An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * TEPEZZA Receives Approval in Japan to Treat TED On Sept. 24, Amgen announced that TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) thyroid eye disease (TED) by Japan’s Ministry of Health, Labour and Welfare (MHLW)....
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Neuroendocrine Tumor Treatment Data Presented by Exelixis On September 16, Exelixis announced updated and final data from CABINET, a Phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort with...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Study Data Support Efficacy of Treatment for Vasomotor Symptoms Associated with Menopause As reported in the Sept. 6 Pharma Fridays, Bayer will present detailed results from the Phase III study OASIS 3, providing supporting efficacy data and sustained safety data over...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Glytec Expands Global Collaboration with Roche to Revolutionize Hospital Diabetes Management Transforming Global Hospital Diabetes Management On August 27, Glytec, announced an expansion of its collaboration with Roche, that will allow the use of Glytec’s software in connection with Roche’s smart-device...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Metabolon Receives NIH Grant to Develop Advanced Monitoring and Predictive Tools for Type 1 Diabetes Progression Morrisville, N.C.- based Metabolon, Inc., has received a grant from the National Institutes of Health (NIH) to develop an innovative product aimed at better monitoring...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors Veracyte, Inc., announced new research findings suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease....
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Xerix Announces Results of Once-Weekly Subcutaneous Hypothyroidism Therapy On May 30, Xeris Biopharma Holdings, Inc., announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company’s...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Clinical Trial Interim Data Show Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome On April 11, Amylyx Pharmaceuticals announced interim data from the ongoing Phase 2 HELIOS clinical trial of AMX0035 (sodium phenylbutyrate [PB] and...
